Aussie regulators approve Baxter's $4B Gambro merger

September 5, 2013 by Arezu Sarvestani

Australian healthcare regulators say they won't block Baxter's $4 billion play for dialysis devices giant Gambro, as long as Baxter ditches its renal replacement therapy division.

Aussie regulators approve Baxter's $4B Gambro merger

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp